Stifel Nicolaus Boosts GH Research (NASDAQ:GHRS) Price Target to $32.00

GH Research (NASDAQ:GHRS) had its price objective increased by analysts at Stifel Nicolaus from $18.00 to $32.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Stifel Nicolaus’ price target would indicate a potential upside of 215.89% from the company’s current price.

A number of other equities analysts also recently issued reports on the company. Cantor Fitzgerald assumed coverage on GH Research in a research note on Thursday, February 13th. They set an “overweight” rating and a $14.00 target price for the company. Canaccord Genuity Group reduced their target price on GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a report on Monday, November 18th. Finally, HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of GH Research in a research report on Monday, January 27th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $30.60.

GH Research Price Performance

NASDAQ:GHRS opened at $10.13 on Thursday. The firm has a market cap of $527.04 million, a price-to-earnings ratio of -12.82 and a beta of 0.93. The firm’s fifty day moving average price is $10.51 and its 200 day moving average price is $9.20. GH Research has a 1-year low of $6.00 and a 1-year high of $20.50.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06. As a group, analysts expect that GH Research will post -0.8 earnings per share for the current fiscal year.

Hedge Funds Weigh In On GH Research

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets purchased a new position in shares of GH Research in the fourth quarter valued at $44,000. Two Sigma Investments LP purchased a new position in GH Research during the 4th quarter valued at about $117,000. Millennium Management LLC purchased a new position in GH Research during the 4th quarter valued at about $145,000. AdvisorShares Investments LLC raised its position in GH Research by 15.4% during the fourth quarter. AdvisorShares Investments LLC now owns 36,011 shares of the company’s stock worth $252,000 after acquiring an additional 4,806 shares during the last quarter. Finally, Northern Trust Corp lifted its holdings in shares of GH Research by 26.8% in the fourth quarter. Northern Trust Corp now owns 40,834 shares of the company’s stock valued at $286,000 after purchasing an additional 8,641 shares in the last quarter. 56.90% of the stock is owned by institutional investors and hedge funds.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).